Predictive Factors of Lamivudine Treatment Success in a Hepatitis B Virus-Infected Pediatric Cohort: A 10-Year Study
BACKGROUND: Hepatitis B virus (HBV) infections are responsible for the development of chronic hepatitis in 400 million people worldwide. Currently, no consensus exists as to when treatment should be initiated for pediatric patients.
Saved in:
Main Authors: | Yasmine Yousef, Kathie Béland, Emmanuel Mas, Pascal Lapierre, Dorothée Bouron Dal Soglio, Fernando Alvarez |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2012/928912 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reassessing the Role for Lamivudine in Chronic Hepatitis B Infection: A Four-Year Cohort Analysis
by: Tahir Shaikh, et al.
Published: (2012-01-01) -
Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis
by: Pascal Lapierre, et al.
Published: (2015-01-01) -
Spectrophotometric Determination of Lamivudine in Pure and Tablet Forms
by: A. Biksham Babu, et al.
Published: (2012-01-01) -
Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade
by: Nanda Kerkar, et al.
Published: (2024-12-01) -
Simultaneous Determination of Lamivudine, Zidovudine and Abacavir in Tablet Dosage Forms by RP HPLC Method
by: D. Anantha Kumar, et al.
Published: (2010-01-01)